Metabolism of xenobiotic carboxylic acids: Focus on coenzyme a conjugation, reactivity, and interference with lipid metabolism

Chemical Research in Toxicology

Volumn 26, Issue 8, 2013, Pages 1139-1155

  Darnell, Malin ^a   Weidolf, Lars ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ARACHIDONIC ACID; BEZAFIBRATE; CARBON DIOXIDE; CARBOXYLIC ACID DERIVATIVE; CARNITINE; COENZYME A; CYTOCHROME P450; DOCOSAHEXAENOIC ACID; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE; IBUPROFEN; LIPID; LONG CHAIN FATTY ACID COENZYME A LIGASE; NAFENOPIN; OCTANOIC ACID; OXYGEN; PALMITIC ACID; PIOGLITAZONE; PROPIONIC ACID; RECOMBINANT CYTOCHROME P450; RECOMBINANT ENZYME; ROSIGLITAZONE; TRIACYLGLYCEROL; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; XENOBIOTIC AGENT; XENOBIOTIC CARBOXYLIC ACID DERIVATIVE;

ARTICLE; BIOTRANSFORMATION; CELL ORGANELLE; CHIRALITY; COVALENT BOND; CYTOTOXICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG CONJUGATION; DRUG INHIBITION; DRUG METABOLISM; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME STABILITY; ENZYME SYNTHESIS; FATTY ACID OXIDATION; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIPID METABOLISM; LIVER MICROSOME; LIVER TOXICITY; MACROMOLECULE; METABOLIC DISORDER; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PROTEIN DEPLETION; SUBSTITUTION REACTION; XENOBIOTIC METABOLISM;

ANIMALS; CARBOXYLIC ACIDS; COENZYME A; COENZYME A LIGASES; GLUCURONIDES; HUMANS; LIPID METABOLISM; LIVER; MICROSOMES, LIVER; MITOCHONDRIA; XENOBIOTICS;

EID: 84882632557     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx400183y     Document Type: Article

References (89)

1. Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2008) Guidance for Industry: Safety Testing of Drug Metabolites, FDA, Silver Spring, MD.
2. Boelsterli, U. A. (2002) Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions Curr. Drug Metab. 3, 439-450
3. Regan, S. L., Maggs, J. L., Hammond, T. G., Lambert, C., Williams, D. P., and Park, B. K. (2010) Acyl glucuronides: the good, the bad and the ugly Biopharm. Drug Dispos. 31, 367-395
4. Grillo, M. P., Lohr, M. T., and Wait, J. C. M. (2012) Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat Drug Metab. Dispos. 40, 1515-1526
5. Li, C., Grillo, M. P., and Benet, L. Z. (2003) In vitro studies on the chemical reactivity of 2,4-dichlorophenoxyacetyl-S-acyl-CoA thioester Toxicol. Appl. Pharmacol. 187, 101-109
6. Olsen, J., Li, C., Skonberg, C., Bjørnsdottir, I., Sidenius, U., Benet, L. Z., and Hansen, S. H. (2007) Studies on the metabolism of tolmetin to the chemically reactive acyl-coenzyme A thioester intermediate in rats Drug Metab. Dispos. 35, 758-764
7. Sallustio, B. C., Nunthasomboon, S., Drogemuller, C. J., and Knights, K. M. (2000) In vitro covalent binding of nafenopin-CoA to human liver proteins Toxicol. Appl. Pharmacol. 163, 176-182
8. Begriche, K., Massart, J., Robin, M. A., Borgne-Sanchez, A., and Fromenty, B. (2011) Drug-induced toxicity on mitochondria and lipid metabolism: Mechanistic diversity and deleterious consequences for the liver J. Hepatol. 54, 773-794
9. Grillo, M. P. and Hua, F. (2008) Enantioselective formation of ibuprofen-S-acyl-glutathione in vitro in incubations of ibuprofen with rat hepatocytes Chem. Res. Toxicol. 21, 1749-1759
10. Grillo, M. P. and Lohr, M. T. (2009) Covalent binding of phenylacetic acid to protein in incubations with freshly isolated rat hepatocytes Drug Metab. Dispos. 37, 1073-1082
11. Grillo, M. P., Wait, J. C. M., Lohr, M. T., Khera, S., and Benet, L. Z. (2010) Stereoselective flunoxaprofen-S-acyl-glutathione thioester formation mediated by acyl-CoA formation in rat hepatocytes Drug Metab. Dispos. 38, 133-142
12. Li, C., Benet, L. Z., and Grillo, M. P. (2002) Enantioselective covalent binding of 2-phenylpropionic Acid to protein in vitro in rat hepatocytes Chem. Res. Toxicol. 15, 1480-1487
13. Li, C., Grillo, M. P., and Benet, L. Z. (2003) In vivo mechanistic studies on the metabolic activation of 2-phenylpropionic acid in rat J. Pharmacol. Exp. Ther. 305, 250-256
14. Li, C., Olurinde, M. O., Hodges, L. M., Grillo, M. P., and Benet, L. Z. (2003) Covalent binding of 2-phenylpropionyl-s-acyl-CoA thioester to tissue proteins in vitro Drug Metab. Dispos. 31, 727-730
15. Li, C., Grillo, M. P., Badagnani, I., Fife, K. L., and Benet, L. Z. (2008) Differential effects of fibrates on the metabolic activation of 2-phenylpropionic acid in rats Drug Metab. Dispos. 36, 682-687
16. Horng, H. and Benet, L. Z. (2013) Characterization of the acyl-adenylate linked metabolite of mefenamic acid Chem. Res. Toxicol. 26, 465-476
17. Olsen, J., Bjørnsdottir, I., and Honoré Hansen, S. (2003) Identification of coenzyme A-related tolmetin metabolites in rats: Relationship with reactive drug metabolites Xenobiotica 33, 561-570
18. Olsen, J., Li, C., Bjørnsdottir, I., Sidenius, U., Hansen, S. H., and Benet, L. Z. (2005) In vitro and in vivo studies on acyl-coenzyme A-dependent bioactivation of zomepirac in rats Chem. Res. Toxicol. 18, 1729-1736
19. Knights, K. M., Sykes, M. J., and Miners, J. O. (2007) Amino acid conjugation: contribution to the metabolism and toxicity of xenobiotic carboxylic acids Expert Opin. Drug Metab. Toxicol. 3, 159-168
20. Knights, K. M., Sykes, M. J., and Miners, J. O. (2007) Amino acid conjugation: Contribution to the metabolism and toxicity of xenobiotic carboxylic acids Expert Opin. Drug Metab. Toxicol. 3, 159-168
21. Mitamura, K., Aoyama, E., Sakai, T., Iida, T., Hofmann, A. F., and Ikegawa, S. (2011) Characterization of non-enzymatic acylation of amino or thiol groups of bionucleophiles by the acyl-adenylate or acyl-CoA thioester of cholic acid Anal. Bioanal Chem. 400, 2253-2259
22. Drogemuller, C. J., Nunthasomboon, S., and Knights, K. M. (2001) Nafenopin-, ciprofibroyl-, and palmitoyl-CoA conjugation in vitro: Kinetic and molecular characterization of marmoset liver microsomes and expressed MLCL1 Arch. Biochem. Biophys. 396, 56-64
23. Kaemmerer, E., Peuscher, A., Reinartz, A., Liedtke, C., Weiskirchen, R., Kopitz, J., and Gassler, N. (2011) Human intestinal acyl-CoA synthetase 5 is sensitive to the inhibitor triacsin C World J. Gastroenterol. 17, 4883-4889
24. Watkins, P. A., Maiguel, D., Jia, Z., and Pevsner, J. (2007) Evidence for 26 distinct acyl-coenzyme A synthetase genes in the human genome J. Lipid Res. 48, 2736-2750
25. Knights, K. M. and Drogemuller, C. J. (2000) Xenobiotic-CoA ligases: Kinetic and molecular characterization Curr. Drug Metab. 1, 49-66
26. Boomgaarden, I., Vock, C., Klapper, M., and Döring, F. (2009) Comparative analyses of disease risk genes belonging to the Acyl-CoA synthetase medium-chain (ACSM) family in human liver and cell lines Biochem. Genet. 47, 739-748
27. Mashek, D. G., Li, L. O., and Coleman, R. A. (2006) Rat long-chain acyl-CoA synthetase mRNA, protein, and activity vary in tissue distribution and in response to diet J. Lipid Res. 47, 2004-2010
28. Grillo, M. P. (2011) Drug-s-acyl-glutathione thioesters: Synthesis, bioanalytical properties, chemical reactivity, biological formation and degradation Curr. Drug Metab. 12, 229-244
29. Lewin, T. M., Kim, J.-H., Granger, D. A., Vance, J. E., and Coleman, R. A. (2001) Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently J. Biol. Chem. 276, 24674-24679
30. Soupene, E. and Kuypers, F. A. (2008) Mammalian long-chain acyl-CoA synthetases Exp. Biol. Med. 233, 507-521
31. Zhao, X. J., Yokoyama, H., Chiba, K., Wanwimolruk, S., and Ishizaki, T. (1996) Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human liver microsomes and nine recombinant human cytochromes P450 J. Pharmacol. Exp. Ther. 279, 1327-1334
32. Mano, Y., Usui, T., and Kamimura, H. (2004) Effects of β-estradiol and propofol on the 4-methylumbelliferone glucuronidation in recombinant human UGT isozymes 1A1, 1A8 and 1A9 Biopharm. Drug Dispos. 25, 339-344
33. Kim, J. H., Lewin, T. M., and Coleman, R. A. (2001) Expression and characterization of recombinant rat Acyl-CoA synthetases 1, 4, and 5. Selective inhibition by triacsin C and thiazolidinediones J. Biol. Chem. 276, 24667-24673
34. Shimshoni, J. A., Basselin, M., Li, L. O., Coleman, R. A., Rapoport, S. I., and Modi, H. R. (2011) Valproate uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: Relevance to valproate's efficacy against bipolar disorder Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1811, 163-169
35. Tracy, T. S., Wirthwein, D. P., and Hall, S. D. (1993) Metabolic inversion of (R)-ibuprofen: Formation of ibuprofenyl-coenzyme A Drug Metab. Dispos. 21, 114-120
36. Knights, K. M. and Roberts, B. J. (1994) Xenobiotic acyl-CoA formation: Evidence of kinetically distinct hepatic microsomal long-chain fatty acid and nafenopin-CoA ligases Chem.-Biol. Interact. 90, 215-224
37. Grillo, M. P. and Benet, L. Z. (2002) Studies on the reactivity of clofibryl-S-acyl-CoA thioester with glutathione in vitro Drug Metab. Dispos. 30, 55-62
38. Li, C., Benet, L. Z., and Grillo, M. P. (2002) Studies on the chemical reactivity of 2-phenylpropionic acid 1-O-acyl glucuronide and S-acyl-CoA thioester metabolites Chem. Res. Toxicol. 15, 1309-1317
39. Sidenius, U., Skonberg, C., Olsen, J., and Hansen, S. H. (2004) In vitro reactivity of carboxylic acid-CoA thioesters with glutathione Chem. Res. Toxicol. 17, 75-81
40. Grillo, M. P. and Hua, F. (2003) Identification of zomepirac-S-acyl- glutathione in vitro in incubations with rat hepatocytes and in vivo in rat bile Drug Metab. Dispos. 31, 1429-1436
41. Grillo, M. P., Knutson, C. G., Sanders, P. E., Waldon, D. J., Hua, F., and Ware, J. A. (2003) Studies on the chemical reactivity of diclofenac acyl glucuronide with glutathione: identification of diclofenac-S-acyl-glutathione in rat bile Drug Metab. Dispos. 31, 1327-1336
42. Olsen, J., Bjørnsdottir, I., Tjørnelund, J., and Hansen, S. H. (2002) Chemical reactivity of the naproxen acyl glucuronide and the naproxen coenzyme A thioester towards bionucleophiles J. Pharm. Biomed. Anal. 29, 7-15
43. Shore, L. J., Fenselau, C., King, A. R., and Dickinson, R. G. (1995) Characterization and formation of the glutathione conjugate of clofibric acid Drug Metab. Dispos. 23, 119-123
44. Bakke, O. M., Manocchia, M., de Abajo, F., Kaitin, K. I., and Lasagna, L. (1995) Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective Clin. Pharmacol. Ther. 58, 108-117
45. Somchit, N., Sanat, F., Gan, E. H., Shahrin, I. A. W., and Zuraini, A. (2004) Liver injury induced by the non-steroidal anti-inflammatory drug mefenamic acid Singapore Med. J. 45, 530-532
46. Lee, C. H., Wang, J. D., and Chen, P. C. (2010) Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs Pharmacoepidemiol. Drug Saf. 19, 708-714
47. Siraki, A. G., Chevaldina, T., and O'Brien, P. J. (2005) Application of quantitative structure-toxicity relationships for acute NSAID cytotoxicity in rat hepatocytes Chem.-Biol. Interact. 151, 177-191
48. Charles, J. M., Bond, D. M., Jeffries, T. K., Yano, B. L., Stott, W. T., Johnson, K. A., Cunny, H. C., Wilson, R. D., and Bus, J. S. (1996) Chronic dietary toxicity/oncogenicity studies on 2,4-dichlorophenoxyacetic acid in rodents Toxicol. Sci. 33, 166-172
49. Leonard, C., Burke, C. M., O'Keane, C., and Doyle, J. S. (1997) 'Golf ball liver': Agent orange hepatitis Gut 40, 687-688
50. Schoonjans, K., Staels, B., Grimaldi, P., and Auwerx, J. (1993) Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation Eur. J. Biochem. 216, 615-622
51. Alegret, M., Ferrando, R., Vazquez, M., Adzet, T., Merlos, M., and Laguna, J. C. (1994) Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates Br. J. Pharmacol. 112, 551-556
52. DailyMed, http://dailymed.nlm.nih.gov/dailymed/about.cfm?CFID= 24634960&CFTOKEN=a143b2b0cf8a571f-D429041D-F5C5-F2B8- 7A03CEF43F77CDD3&jsessionid=8430601e71298b08962b465aa6530417d503 (accessed Oct, 2012).
53. Dodds, P. F. (1995) Xenobiotic lipids: the inclusion of xenobiotic compounds in pathways of lipid biosynthesis Prog. Lipid Res. 34, 219-247
54. Fromenty, B. and Pessayre, D. (1995) Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity Pharmacol. Ther. 67, 101-154
55. McMurry, L. M., Oethinger, M., and Levy, S. B. (1998) Triclosan targets lipid synthesis Nature 394, 531-532
56. Escalada, M. G., Harwood, J. L., Maillard, J. Y., and Ochs, D. (2005) Triclosan inhibition of fatty acid synthesis and its effect on growth of Escherichia coli and Pseudomonas aeruginosa J. Antimicrob. Chemother. 55, 879-882
57. Mayer, J. M., Roy-De Vos, M., Audergon, C., Testa, B., and Etter, J. C. (1994) Interactions of anti-inflammatory 2-arylpropionates (profens) with the metabolism of fatty acids: In vitro studies Int. J. Tissue React. 16, 59-72
58. Dodds, P. F., Chou, S. C., Ranasinghe, A., and Coleman, R. A. (1995) Metabolism of fenbufen by cultured 3T3-L1 adipocytes: synthesis and metabolism of xenobiotic glycerolipids J. Lipid Res. 36, 2493-2503
59. Woodman, T. J., Wood, P. J., Thompson, A. S., Hutchings, T. J., Steel, G. R., Jiao, P., Threadgill, M. D., and Lloyd, M. D. (2011) Chiral inversion of 2-arylpropionyl-CoA esters by human alpha-methylacyl-CoA racemase 1A (P504S)-a potential mechanism for the anti-cancer effects of ibuprofen Chem. Commun. (Cambridge, U.K.) 47, 7332-7334
60. Lloyd, M. D., Darley, D. J., Wierzbicki, A. S., and Threadgill, M. D. (2008) Alpha-methylacyl-CoA racemase-an 'obscure' metabolic enzyme takes centre stage FEBS J. 275, 1089-1102
61. Gao, L. B., Wang, J. Z., Yao, T. W., and Zeng, S. (2012) Study on the metabolic mechanism of chiral inversion of S-mandelic acid in vitro Chirality 24, 86-95
62. Ito, T. (2009) Children's toxicology from bench to bed-liver injury (1): Drug-induced metabolic disturbance-toxicity of 5-FU for pyrimidine metabolic disorders and pivalic acid for carnitine metabolism J. Toxicol. Sci. 34, SP217-SP222
63. Melegh, B., Kerner, J., and Bieber, L. L. (1987) Pivampicillin-promoted excretion of pivaloylcarnitine in humans Biochem. Pharmacol. 36, 3405-3409
64. Laub, M. C., Paetzke-Brunner, I., and Jaeger, G. (1986) Serum carnitine during valproic acid therapy Epilepsia 27, 559-562
65. Quistad, G. B., Staiger, L. E., and Schooley, D. A. (1986) The role of carnitine in the conjugation of acidic xenobiotics Drug Metab. Dispos. 14, 521-525
66. Egawa, T., Toda, K., Nemoto, Y., Ono, M., Akisawa, N., Saibara, T., Hayashi, Y., Hiroi, M., Enzan, H., and Onishi, S. (2003) Pitavastatin ameliorates severe hepatic steatosis in aromatase-deficient (Ar-/-) mice Lipids 38, 519-523
67. Cherkaoui-Malki, M., Surapureddi, S., El-Hajj, H. I., Vamecq, J., and Andreoletti, P. (2012) Hepatic steatosis and peroxisomal fatty acid beta-oxidation Curr. Drug Metab. 13, 1412-1421
68. Mahmud, T., Rafi, S. S., Scott, D. L., Wrigglesworth, J. M., and Bjarnason, I. (1996) Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation Arthritis Rheum. 39, 1998-2003
69. McLaughlin, S. G. and Dilger, J. P. (1980) Transport of protons across membranes by weak acids Physiol. Rev. 60, 825-863
70. Krause, M. M., Brand, M. D., Krauss, S., Meisel, C., Vergin, H., Burmester, G. R., and Buttgereit, F. (2003) Nonsteroidal antiinflammatory drugs and a selective cyclooxygenase 2 inhibitor uncouple mitochondria in intact cells Arthritis Rheum. 48, 1438-1444
71. Leite, S., Martins, N. M., Dorta, D. J., Curti, C., Uyemura, S. A., and Cardozo Dos Santos, A. (2006) Mitochondrial uncoupling by the sulindac metabolite, sulindac sulfide Basic Clin. Pharmacol. Toxicol. 99, 294-299
72. Freneaux, E., Fromently, B., Berson, A., Labbe, G., Degott, C., Letteron, P., Larrey, D., and Pessayre, D. (1990) Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial β-oxidation of fatty acids J. Pharmacol. Exp. Ther. 255, 529-535
73. Browne, G. S., Nelson, C., Nguyen, T., Ellis, B. A., Day, R. O., and Williams, K. M. (1999) Stereoselective and substrate-dependent inhibition of hepatic mitochondrial β-oxidation and oxidative phosphorylation by the non-steroidal anti inflammatory drugs ibuprofen, flurbiprofen, and ketorolac Biochem. Pharmacol. 57, 837-844
74. Jin, Y., Zollinger, M., Borell, H., Zimmerlin, A., and Patten, C. J. (2011) CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis Drug Metab. Dispos. 39, 191-198
75. Darnell, M., Ulvestad, M., Ellis, E., Weidolf, L., and Andersson, T. B. (2012) In vitro evaluation of major in vivo drug metabolic pathways using primary human hepatocytes and HepaRG cells in suspension and a dynamic three-dimensional bioreactor system J. Pharmacol. Exp. Ther. 343, 134-144
76. Diao, X., Deng, P., Xie, C., Li, X., Zhong, D., Zhang, Y., and Chen, X. (2013) Metabolism and pharmacokinetics of 3-n-butylphthalide (NBP) in humans: the role of cytochrome P450s and alcohol dehydrogenase in biotransformation Drug Metab. Dispos. 41, 430-444
77. Fer, M., Corcos, L., Dréano, Y., Plée-Gautier, E., Salaün, J. P., Berthou, F., and Amet, Y. (2008) Cytochromes P450 from family 4 are the main omega hydroxylating enzymes in humans: CYP4F3B is the prominent player in PUFA metabolism J. Lipid Res. 49, 2379-2389
78. Hashizume, T., Imaoka, S., Mise, M., Terauchi, Y., Fujii, T., Miyazaki, H., Kamataki, T., and Funae, Y. (2002) Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes J. Pharmacol. Exp. Ther. 300, 298-304
79. Bauman, J. N., Kelly, J. M., Tripathy, S., Zhao, S. X., Lam, W. W., Kalgutkar, A. S., and Obach, R. S. (2009) Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction Chem. Res. Toxicol. 22, 332-340
80. Thompson, R. A., Isin, E. M., Li, Y., Weidolf, L., Page, K., Wilson, I., Swallow, S., Middleton, B., Stahl, S., Foster, A. J., Dolgos, H., Weaver, R., and Kenna, J. G. (2012) In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs Chem. Res. Toxicol. 25, 1616-1632
81. Masubuchi, Y., Saito, H., and Horie, T. (1998) Structural requirements for the hepatotoxicity of nonsteroidal anti-inflammatory drugs in isolated rat hepatocytes J. Pharmacol. Exp. Ther. 287, 208-213
82. Thompson, R. A., Isin, E. M., Li, Y., Weaver, R., Weidolf, L., Wilson, I., Claesson, A., Page, K., Dolgos, H., and Kenna, J. G. (2011) Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development Chem.-Biol. Interact. 192, 65-71
83. Wensaas, A. J., Rustan, A. C., Lövstedt, K., Kull, B., Wikström, S., Drevon, C. A., and Hallén, S. (2007) Cell-based multiwell assays for the detection of substrate accumulation and oxidation J. Lipid Res. 48, 961-967
84. Porceddu, M., Buron, N., Roussel, C., Labbe, G., Fromenty, B., and Borgne-Sanchez, A. (2012) Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria Toxicol. Sci. 129, 332-345
85. Boelsterli, U. A. and Lim, P. L. K. (2007) Mitochondrial abnormalities-A link to idiosyncratic drug hepatotoxicity? Toxicol. Appl. Pharmacol. 220, 92-107
86. Amacher, D. E. (2012) The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury Expert Opin. Drug Metab. Toxicol. 8, 335-347
87. Luo, Y., Rana, P., and Will, Y. (2012) Palmitate increases the susceptibility of cells to drug-induced toxicity: An in vitro method to identify drugs with potential contraindications in patients with metabolic disease Toxicol. Sci. 129, 346-362
88. Kanebratt, K. P. and Andersson, T. B. (2008) Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies Drug Metab. Dispos. 36, 1444-1452
89. Smeitink, J., van den Heuvel, L., and DiMauro, S. (2001) The genetics and pathology of oxidative phosphorylation Nat. Rev. Genet. 2, 342-352